Storys zum Thema Chemie

Gerresheimer AG

Gerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU*

Accord Healthcare

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

London (ots/PRNewswire) - - Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases. - The EC approval follows a positive opinion issued on 19 October ...

Obrist Group

Obrist Group Introduces Alternatives to PFAS and F-Gases

Obrist Group Introduces Alternatives to PFAS and F-Gases Natural Refrigerants Replacing Harmful Forever Chemicals in Cars Lindau/Germany, Lustenau/Austria – December 10 2024 – Per- and polyfluoroalkyl substances (PFAS) are recognized as highly hazardous, and the European Union is preparing to ban these toxic chemicals. The PFAS group also includes F-gases, such as hydrofluorocarbons, which are widely used in cooling ...

Technische Universität München

Removing hazardous PFAS chemicals from drinking water

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE TUM researchers develop highly effective filter material Removing hazardous PFAS chemicals from drinking water - Metal-organic framework compounds made of zirconium carboxylate as filters - Large-scale use in practice still to come - Contaminated sites caused by PFAS will be with us for several generations ahead The chemicals known as PFAS are considered a severe threat to ...

Obrist Group

Obrist Group: Methanol as the Ideal Fossil Fuel Replacement for Key Industries

Strides Pharma International AG

Strides Pharma Consolidates European Business-to-Business Operations in Switzerland

nova-Institut GmbH

6

Capture, Convert, and Conquer: Innovations Wanted for the “Best CO₂ Utilisation 2025” Innovation Award

Aurubis AG

Press release: Aurubis investing € 40 million in more independent and efficient production in Lünen

Grünenthal Group

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain

Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...

LAUDA DR. R. WOBSER GMBH & CO. KG

40th work anniversary at the world market leader

nova-Institut GmbH

5

Advanced Recycling Conference 2024 – Driving Innovation in Sustainable Materials Management

Technische Universität München

Significant Extension of Zinc Battery Lifespan

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE TUM Researchers Develop New Chemical Method for Improved Energy Storage Significant Extension of Zinc Battery Lifespan - Improvement to several hundred thousand charge cycles - Protective layer for zinc anode - Important result in basic research - Large-scale engineering implementation still pending The transition to renewable energy requires efficient methods for storing large ...

Grünenthal Group

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist

Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...

Obrist Group

Obrist Group: Modern Forest is 30 Times Better for the Climate Than Traditional Forests

hubergroup Deutschland GmbH

4

Press Release - hubergroup showcases Innovative Solutions at EURASIA PACKAGING FAIR 2024

Epitomee Medical

Epitomee Medical to Present the Epitomee Breakthrough Oral Delivery Platform at PODD 2024 Conference

Caesarea, Israel (ots/PRNewswire) - Epitomee Medical Ltd. (TASE: EPIT) announces today that the company leadership intends to present Epitomee's Oral Delivery of Biologics Platform at the 14th Annual PODD Conference - Partnership Opportunities in Drug Delivery, taking place in Boston, MA, October 28-29, 2024. ...

STADA Arzneimittel AG

Press Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar

EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...

Obrist Group

Obrist Group Now Open for Institutional Investors

Epitomee Medical

Epitomee Medical Announces FDA Clearance of its Capsule, Weight Management Device

Caesarea, Israel (ots/PRNewswire) - Epitomee's Ingestible Capsule, Offers a Safe and Effective Prescription Solution for Adults with BMI of 25-40 looking for Alternative Drug Free Solutions for Their Weight Management Needs alongside diet and exercise. Epitomee Medical Ltd. (TASE: EPIT), announced that the United States Food and Drug Administration (FDA) has officially ...

Scantox A/S

Scantox Group acquires Gentronix, a world leader in genetic toxicology

Ejby, Denmark (ots/PRNewswire) - Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization ("CRO"). Gentronix, now integrated into Scantox Group, is well recognized for its high-quality genetic toxicology services and strong scientific engagement, with ...

hubergroup Deutschland GmbH

6

Press Release - hubergroup is Cradle to Cradle certified for the fourth time in a row

PCC SE

PCC BakkiSilicon hf. receives ISCC Carbon Footprint Certification for critical raw material silicon / PCC subsidiary becomes first silicon producer to receive ISCC certification for carbon footprint

nova-Institut GmbH

5

Advanced Recycling Conference 2024: New Focus Areas and Innovative Program Announced

nova-Institut GmbH

4

CO₂-based Fuels and Chemicals Conference 2025 – Call for Abstracts and Posters